SUZHOU, China, Nov. 21, 2025 /PRNewswire/ -- On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market ...
Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission ...
Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update. Lepu Biopharma Co., Ltd. has announced positive clinical trial results for its innovative drugs and combination therapies at the ASCO ...
The U.S. Food and Drug Administration today said it is “warning the public” to stop using a SARS-CoV-2 antigen rapid test kit and antibody rapid test kit because, it said, “there is likely a high risk ...
CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive ...
The China NMPA’s Center for Drug Evaluation accepted Lepu Biopharma Co. Ltd.’s new drug application (NDA) for anti-PD-1 antibody candidate HX-008 (pucotenlimab). That comes after the company filed for ...
After taking its Lepu Biopharma unit public in February, Lepu Medical is pressing ahead with a third attempt at listing is Lepu ScienTech unit in Hong Kong China’s healthcare regulator has said it won ...
Lepu Biopharma Co. Ltd. has been given conditional approval by China’s NMPA for its anti-PD-1 monoclonal antibody, Puyouheng (pucotenlimab injection), based on data from a phase II study. The drug was ...
All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results